Literature DB >> 11447072

Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.

S F Nagueh1, L L Bachinski, D Meyer, R Hill, W A Zoghbi, J W Tam, M A Quiñones, R Roberts, A J Marian.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH), the clinical hallmark of familial hypertrophic cardiomyopathy (FHCM), is absent in a significant number of subjects with causal mutations. In transgenic rabbits that fully recapitulate the FHCM phenotype, reduced myocardial tissue Doppler (TD) velocities accurately identified the mutant rabbits, even in the absence of LVH. We tested whether humans with FHCM also consistently showed reduced myocardial TD velocities, irrespective of LVH. METHODS AND
RESULTS: We performed 2D and Doppler echocardiography and TD imaging in 30 subjects with FHCM, 13 subjects who were positive for various mutations but did not have LVH, and 30 age- and sex-matched controls (all adults; 77% women). LV wall thickness and mass were significantly greater in FHCM subjects (P<0.01 versus those without LVH and controls). There were no significant differences in 2D echocardiographic, mitral, and pulmonary venous flow indices between mutation-positives without LVH and controls. In contrast, systolic and early diastolic TD velocities were significantly lower in both mutation-positives without LVH and in FHCM patients than in controls (P<0.001). Reduced TD velocities had a sensitivity of 100% and a specificity of 93% for identifying mutation-positives without LVH.
CONCLUSIONS: Myocardial contraction and relaxation velocities, detected by TD imaging, are reduced in FHCM, including in those without LVH. Before and independently of LVH, TD imaging is an accurate and sensitive method for identifying subjects who are positive for FHCM mutations.

Entities:  

Mesh:

Year:  2001        PMID: 11447072      PMCID: PMC2900859          DOI: 10.1161/01.cir.104.2.128

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

Review 2.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

3.  Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  S F Nagueh; H A Kopelen; D S Lim; W A Zoghbi; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

4.  Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy.

Authors:  S F Nagueh; N M Lakkis; K J Middleton; W H Spencer; W A Zoghbi; M A Quiñones
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

5.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

Review 6.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

7.  A transgenic rabbit model for human hypertrophic cardiomyopathy.

Authors:  A J Marian; Y Wu; D S Lim; M McCluggage; K Youker; Q T Yu; R Brugada; F DeMayo; M Quinones; R Roberts
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

8.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles.

Authors:  B J Maron; J Shirani; L C Poliac; R Mathenge; W C Roberts; F O Mueller
Journal:  JAMA       Date:  1996-07-17       Impact factor: 56.272

9.  Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.

Authors:  D S Lim; S Lutucuta; P Bachireddy; K Youker; A Evans; M Entman; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

  9 in total
  122 in total

1.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

2.  Can an energy-deficient heart grow bigger and stronger?

Authors:  Robert Roberts; Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

3.  Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.

Authors:  Sherif F Nagueh; Judy McFalls; Denise Meyer; Rita Hill; William A Zoghbi; James W Tam; Miguel A Quiñones; Robert Roberts; A J Marian
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

4.  Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function.

Authors:  D Pellerin; R Sharma; P Elliott; C Veyrat
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

5.  Clinical applications of tissue Doppler imaging: a promise fulfilled.

Authors:  T H Marwick
Journal:  Heart       Date:  2003-12       Impact factor: 5.994

Review 6.  Echocardiography: frontier imaging in cardiology.

Authors:  R P Steeds
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 7.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

8.  Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy.

Authors:  Sabe De; Allen G Borowski; Heng Wang; Leah Nye; Baozhong Xin; James D Thomas; W H Wilson Tang
Journal:  Am Heart J       Date:  2011-07-18       Impact factor: 4.749

Review 9.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

Review 10.  Principles of transthoracic echocardiographic evaluation.

Authors:  Anita C Boyd; Nelson B Schiller; Liza Thomas
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.